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Drug Delivery
Increasing interests have been raised toward the potential applications of biodegradable
poly(lactic-co-glycolic acid) (PLGA) coatings for drug-eluting stents in order to improve
the drug delivery and reduce adverse outcomes in stented arteries in patients. This article
presents a mathematical model to describe the integrated processes of drug release in a
stent with PLGA coating and subsequent drug delivery, distribution, and drug pharmaco-
kinetics in the arterial wall. The integrated model takes into account the PLGA degrada-
tion and erosion, anisotropic drug diffusion in the arterial wall, and reversible drug
binding. The model simulations first compare the drug delivery from a biodegradable
PLGA coating with that from a biodurable coating, including the drug release profiles in
the coating, average arterial drug levels, and arterial drug distribution. Using the model
for the PLGA stent coating, the simulations further investigate drug internalization, inter-
stitial fluid flow in the arterial wall, and stent embedment for their impact on drug deliv-
ery. Simulation results show that these three factors, while imposing little change in the
drug release profiles, can greatly change the average drug concentrations in the arterial
wall. In particular, each of the factors leads to significant and yet distinguished altera-
tions in the arterial drug distribution that can potentially influence the treatment out-
comes. The detailed integrated model provides insights into the design and evaluation of
biodegradable PLGA-coated drug-eluting stents for improved intravascular drug
delivery. [DOI: 10.1115/1.4028135]
Keywords: drug-eluting stents, mathematical modeling, PLGA biodegradable coating,
intravascular delivery, drug internalization, interstitial fluid flow, strut embedment
1 Introduction
Drug-eluting stents are commonly used in the coronary angio-
plasty procedures to both provide structural support and release
drug molecules locally at the implanted arterial site for preventing
adverse outcomes (such as in-stent restenosis) in the patients
[1–3]. Biodurable (or nonerodible) polymers are the predominant
type of stent coatings for carrying active drug compounds,
whereas recent studies have suggested issues potentially related to
the slow drug release in the biodurable coatings and the hypersen-
sitivity to the permanent presence of polymer coating in the
arterial wall [4–7]. Improving the design and performance of
drug-eluting stents is a long-term research topic. Among the vari-
ous research directions, the utilization of biodegradable polymer
coatings in place of the biodurable coatings has been proposed
[8,9]. In particular, biocompatible PLGA, and allows tunable drug
release rates based on different polymer molecular weights, has
received a high amount of interest in ongoing drug-eluting stents
research [10–14]. While most studies were carried out for exami-
nation of release under in vitro conditions, further evaluation of
PLGA stent coating for in vivo evaluations of implanted stents are
necessary and are typically significantly more costly.
Mathematical models and simulations have been widely
employed in the research of drug-eluting stents ranging from
in vitro drug release evaluation to intravascular delivery
investigations. Especially, models for studying the intravascular
drug delivery process can help to acquire detailed information
about the drug release, delivery, and distribution into the arterial
wall, and can provide additional insights into the stent-based drug
delivery systems. Some models simplifies the stent coating into a
source term for providing drug concentrations, and focus on inves-
tigating the arterial drug distribution surrounding the stent struts
without explicitly modeling the drug transport in the stent coating.
Such models were used in the analysis of convective and diffusive
drug transport comparison in the arterial wall [15], mechanics of
stent expansion and drug distribution [16], and impact of blood
flow on drug deposition in the arterial wall [17,18]. Other models
have incorporated the biodurable coating to model the drug
release from the coating and subsequent drug uptake in the arterial
wall. In those models where the biodurable coating is explicitly
modeled with a constant drug diffusivity, drug release, and arterial
drug distribution have been investigated considering the effects of
drug diffusivities in the coating and in the arterial wall [19–22],
coating thickness [19], the strut embedment [20] and compression
[23], reversible drug binding [22,24], and multilayer structure of
the arterial wall [25,26].
So far little modeling work has been published on intravascular
drug delivery using biodegradable stent coatings. A degradable
stent coating has been modeled by artificially switching the values
of drug diffusivity in the coating reservoir based on a predefined
drug concentration threshold [27], which does not mechanistically
model the coating erosion process. While various models have
been proposed for describing the in vitro drug release coupled
with polymer degradation and/or erosion in PLGA drug delivery
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systems (for microspheres [28–30] and thin film stent coatings
[31,32]), such mechanistic models have not been utilized to model
the intravascular drug delivery from a PLGA stent coating.
This work presents a mathematical model that describes the
integrated process of drug release in PLGA coating and subse-
quent drug delivery, distribution, and drug pharmacokinetics in
the arterial wall. A mechanistic model for drug release in the
PLGA coating is adopted that couples the drug diffusion to the
PLGA degradation and erosion [32], and the adopted model is
integrated with an arterial wall model where the drug pharmacoki-
netics in the arterial wall is modeled as a reversible binding pro-
cess [22]. The integrated model further incorporates drug
internalization for cellular drug uptake, interstitial fluid flow, and
strut embedment as model factors. For drug diffusion in the arte-
rial wall, an anisotropic drug diffusivity is considered and is ana-
lytically calculated based on the structural properties of the
arterial wall. The model is simulated using the finite element
method. The simulations first compare the biodegradable PLGA
coating with a biodurable coating for stent-based drug delivery.
For a stent with PLGA coating, the model simulations further
investigate the impact of drug internalization, interstitial fluid
flow in the arterial wall, and stent embedment on drug release in
the coating, arterial drug levels, and arterial drug distribution. De-
velopment of such a detailed integrated model helps to provide
insights into the design and evaluation of biodegradable PLGA
coated drug-eluting stents for intravascular drug delivery.
2 Theory and Methods
2.1 Model Development. In the model scheme, an implanted
stent is studied in the artery where the stent struts are evenly
placed in the cross section of the lumen (Fig. 1(a)). The strut-
arterial wall configuration is based on a previous study of a bio-
durable polymer coating carried out by the authors [22] and is
typical for stents applications [15]. The blood flow is in the direc-
tion into the paper plane. Typical square-shaped stent struts are
considered [19,25,33]. Due to symmetry, a single stent strut with
its surrounding arterial wall domain is extracted for the study to
reduce computational cost. The extracted model domain is illus-
trated in Fig. 1(b), where half of the stent strut is embedded into
the arterial wall. Different from the previous study of biodurable
coatings [22], here the curvature of the arterial wall is retained
rather than simplified as being flat. The Cartesian coordinate sys-
tem (noted as x, y) is used for describing the domains including
the square-shaped stent strut and the stent coating, and the cylin-
drical coordinate (noted as r, h) is adopted for the curved arterial
wall domain.
The mathematical models for important phenomena governing
the drug delivery process are described in Secs. 2.1.1 and 2.1.2.
The model for describing drug transport in the biodegradable
PLGA coating was adapted from Ref. [32], and the model for
drug transport and pharmacokinetics in the arterial wall was
developed based on a previous study for biodurable coating [22].
The integrated model provides a tool for evaluating PLGA-coated
drug-eluting stents for intravascular drug delivery.
2.1.1 Drug Transport in the PLGA Coating. The drug release
in the PLGA polymer coating is a process coupled to the degrada-
tion and erosion of the PLGA polymer matrix. Degradation repre-
sents the chemical process that breaks down the polymer chains
and results in decreasing PLGA molecular weight, and erosion is
the physical process characterized by the polymer mass loss [34].
Both degradation and erosion can facilitate drug molecule diffu-
sion, as molecular weight reduction induces less entanglement of
polymer chains in the PLGA bulk, and the mass loss creates pore
space. For PLGA microsphere systems, a good number of mathe-
matical models have been proposed in the literature to describe the
degradation and erosion process of PLGA microspheres and to take
into account the degradation and/or erosion contribution in the drug
release process [28–30]. The proposed models typically incorporate
a variable drug diffusivity that depends solely on the PLGA molec-
ular weight change [35–38]. An exponential dependency of drug
diffusivity on the concentration of undegraded poly(lactic acid)
(PLA) was also seem in a model for PLA stent coating [31]. In a
recent work of the authors, a model was proposed for drug release
in PLGA stent coating that considers contributions to the effective
drug diffusivity from both degradation and erosion of PLGA [32],
where the importance of dual contributions in the effective drug dif-
fusivity was validated and demonstrated for in vitro sirolimus
release from PLGA coating. The model is utilized here to describe
the drug diffusion in the PLGA coating coupled to polymer degra-
dation and erosion; readers interested in the detailed derivation of
the mathematical model are referred to Ref. [32].
The drug diffusion through both the polymer bulk with decreas-
ing PLGA molecular weight and the pore space with increasing
pore volume fraction in the matrix is described by incorporating
an effective drug diffusivity. The drug transport in the PLGA
coating is modeled by
@C
@t
¼ D1;e @
2C
@x2
þ D1;e @
2C
@y2
(1)
where D1,e is the effective drug diffusivity in the PLGA coating
and is described by
D1;e ¼ ð1 /ÞDs0 Mw=Mw0ð Þ
aþj/Dl0
1 /þ j/ (2)
The effective diffusivity is a function dependent on the changing
PLGA molecular weight Mw and the evolving coating porosity /.
Ds0 is the initial drug diffusivity in the PLGA polymer before deg-
radation, Dl0 is the drug diffusivity in the aqueous phase, Mw0 is
the initial polymer molecular weight, a is the dependency of drug
Fig. 1 (a) Cross-sectional view of an implanted stent in a coro-
nary artery. (b) Schematic of a single stent strut with PLGA
coating half-embedded into the arterial wall. Cartesian coordi-
nate (x, y) and cylindrical coordinate (r, h) are both illustrated.
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diffusivity on PLGA molecular weight, and k is the drug partition
coefficient between PLGA solid and aqueous phase (defined as
concentration in aqueous phase divided by concentration in the
solid phase at equilibrium).
The PLGA molecular weight change is described by a first-
order decay model given by [35–37]
Mw ¼ Mw0ekwt (3)
The porosity change, which is related to the mass loss of the coat-
ing, was analytically derived as [32]
/ ¼ /0 þ 1 /0ð Þ 1þ e2knt  2eknt
 
(4)
where /0 is the initial porosity in the PLGA polymer matrix and
is assumed zero.
In Eqs. (3) and (4), the kw and kn are degradation rate constants
corresponding to weight- and number-average molecular weight
change, respectively, and their values were experimentally meas-
ured [39]. Equations (1)–(4) provide the complete set of equations
for describing drug transport in the PLGA coating. As PLGA
undergoes bulk erosion, the coating experiences mass loss while
the integral structure is maintained. The coating structure has
been reported to maintain integrity during the entire degradation
period, until much later time after complete elution of the loaded
drug [10]. Therefore, the coating domain can be considered as
intact for the time span of interest.
2.1.2 Drug Transport in the Arterial Wall. Once released into
the arterial wall, the drug molecules are exposed to the physiologi-
cal environment in the arterial wall. While drug molecules diffuse
within the arterial wall, various drug-tissue interactions occur that
affect the arterial wall drug transport, distribution, and drug
uptake [40,41]. The drug-arterial wall interaction has been com-
monly modeled as a reversible binding reaction of the drug mole-
cules with binding sites present in the arterial wall, as shown in
Eq. (5) [22,24,27,41]. In the process, bound drug CB is formed by
associating free drug CF with the available binding sites S. The
bound drug is immobilized and only the free drug can diffuse. The
reversible binding process, however, does not provide a mecha-
nism for drug consumption (e.g., drug uptake by tissue cells),
which can be characterized by drug internalization [42–44]. To
take this factor into account, drug internalization (Eq. (6)) is mod-
eled in this model which assumes that, once drug molecules are
associated with binding sites, the cells take up and metabolize
drug molecules as a first-order reaction. The internalization step,
as a result, regenerates a binding site S for every internalized drug
molecule Cl
Drug binding : CF þ S !ka 
kd
CB (5)
Drug internalization : CB !ki Sþ CI (6)
The drug transport and interactions in the arterial wall are
described for the three drug forms in Eqs. (7)–(9). The cylindrical
coordinate system is used for the arterial wall domain for handling
the curvature (Fig. 1(b))
Free drug :
@CF
@t
þ vr @CF
@r
¼ 1
r
@
@r
rDr
@CF
@r
 
þ Dh
r2
@2CF
@h2
 ka S0  CBð ÞCF þ kdCB (7)
Bound drug :
@CB
@t
¼ ka S0  CBð ÞCF  kdCB  kiCB (8)
Internalized drug :
@CI
@t
¼ kiCB (9)
where S0 is the initial concentration of binding sites in the arterial
wall. Among the three drug forms, only the free drug is able to
diffuse within the arterial wall (Eq. (7)). The equation describes
two different drug diffusivities in the arterial wall: Dh in the cir-
cumferential direction and Dr in the transmural direction. A con-
vective transport term is also included for investigation of the
potential impact of transmural interstitial flow in the arterial wall
with velocity vr , which is driven by the pressure difference
between the lumen and the perivascular space [45]. For correspon-
dence to scenarios where drug internalization and interstitial fluid
flow were not modeled, the factors can be turned off by setting the
internalization rate constant ki and the interstitial fluid flow veloc-
ity vr to zero.
Because of the elongated shape of smooth muscle cells and the
consequent anisotropic arterial wall property, arterial drug diffu-
sion in the transmural direction is hindered, which results in a
much smaller apparent drug diffusivity in the transmural direction
than that of the circumferential direction [46]. The anisotropic
drug diffusivity in the arterial wall has been investigated and
revealed impact on drug delivery and distribution in a few studies,
where the anisotropic ratio was either treated as a parameter or
had empirical values [15,22,25]. Theoretical quantification of the
drug diffusivity anisotropic ratio, however, does not seem to be
published in the literature. In this model, the anisotropic diffusiv-
ity is analytically quantified by adopting the expression for esti-
mating effective diffusivity in periodic composite with
impermeable flakes [47]
Dh
Dr
¼ 1
1þ a2/2F=ð1 /FÞ
(10)
where a is the aspect ratio of smooth muscle cells (defined as the
smaller cell dimension in the circumferential direction divided by
the cell thickness in the transmural direction) and /F is the vol-
ume fraction of smooth muscle cells in the arterial wall. With the
volume fraction of smooth muscle cells measured as 60–70%
[48], and consider an aspect ratio of 3 [49,50], the expression esti-
mates an anisotropic diffusivity ratio Dh/Dr of 9.1–15.7. The esti-
mated range correspond to the reported values (around 10) fairly
well [15]. For larger aspect ratio of the cells, even higher aniso-
tropic ratio could be expected through the estimate of expression.
In this work, an anisotropic ratio of 10 is used throughout the
simulations.
2.2 Numerical Simulation. With appropriate boundary con-
ditions and initial conditions, the integrated model can be solved
for the domain described in Fig. 1(b). For the simulation studies,
zero drug concentration is assumed at the coating-lumen interface
considering a wash-out condition by the bloodstream, and also at
the perivascular interface considering drug clearance [15,24]. At
the arterial wall-lumen interface, the drug flux into the lumen is
assumed as zero considering the barrier effect of the endothelial
layer and the typically high hydrophobicity for drugs used in
drug-eluting stents (such as sirolimus and paclitaxel) that lead to
very limited drug dissipation into the bloodstream from the arte-
rial wall [20,22,27]. The no flux boundary condition is also
applied to the left and right boundaries based on symmetry, and at
the coating-strut interface. At the coating-arterial wall interface,
an equal flux constraint and equal concentration partitioning are
applied. For the initial conditions, the drug is initially uniformly
distributed only in the coating.
While the models proposed here are generally applicable, the
model parameters can vary depending on the different drugs. For
the simulation studies, the model parameters are based on siroli-
mus. However, little information for drug internalization is avail-
able. In order to investigate the internalization factor, a range of its
rate constant values is considered with respect to the dissociation
binding rate constant (Sec. 3.2). The dimensions defining the model
domain and the model parameters are summarized in Table 1.
The mathematical model with domains shown in Fig. 1(b) was
implemented in COMSOL 4.2, which is a simulation platform
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based on the finite element method. The model domains consist of
a single stent strut with coating and the surrounding arterial wall
with curvature. The coating and arterial wall domains are meshed
as illustrated in Fig. 2, where the actual mesh for simulations was
much finer. Considering the much smaller scale of the coating do-
main, a finer mesh in the coating than the arterial wall is used.
Boundary layers with smaller mesh size are also imposed at inter-
faces with nonzero flux (coating-lumen interface, coating-arterial
wall interface, and perivascular interface) to improve the simula-
tion accuracy.
A thorough mesh convergence test was carried out for deter-
mining the mesh sizes for model simulations (Fig. 3). The conver-
gence test is performed with constant drug diffusivities in the
coating and in the arterial wall, and the relative error was calcu-
lated for the drug release profile based on an extremely fine refer-
ence mesh. The reference mesh uses sizes of 0.2 lm for the
coating and 2lm for the arterial wall, and contains 2 106 cells.
In the convergence test, the relative errors were similar and
stayed under 0.5% for different mesh size of the arterial wall do-
main, while the mesh size of the coating is remained the same at
1 lm (Fig. 3(a)). Choosing a mesh size of 5lm for the arterial
wall domain, a mesh size of 0.5 lm was selected for the coating
(Fig. 3(b)). The final mesh gives relative error of less than 0.1%
and contains 257,712 cells.
3 Results and Discussion
In this section, the model simulations first compare the intravas-
cular drug delivery from a biodegradable PLGA coating with that
from a biodurable polymer coating. Following that, using the
model developed for PLGA-coated stent, the drug internalization
rate, interstitial fluid flow, and strut embedment are individually
investigated for their impact on the drug transport and distribu-
tion. In the model simulations, unless mentioned, half strut
embedment is considered and the internalization rate constant ki
and the interstitial fluid flow velocity vr are both set to zero, for
the purpose of comparing with previous modeling work and
inspecting the impact of individual model factors.
The simulation results are reported for drug release profiles in
the coating, average drug levels in the arterial wall for the differ-
ent drug forms, and the spatial drug concentration distribution in
the arterial wall. Specifically, the average drug concentration in
the arterial wall is defined as the spatial average of each drug
form. The three means of characterizing the drug delivery process
are consistent with other modeling works, while offering the pos-
sibility for potential comparison with future experimental
measurements.
3.1 Comparing PLGA Coating With Biodurable Coating.
In model simulations, the PLGA coating is compared with a bio-
durable coating for stent-based intravascular drug delivery. In the
biodurable stent coating case where the polymer coating stays
intact, the drug diffusivity in the coating remains constant at the
initial drug diffusivity in the polymer (Ds0). The rest of the model
parameters are the same for the two scenarios. In the drug release
profiles in the coating (Fig. 4), the two scenarios start with similar
release rates in the first two days when the PLGA degradation and
erosion are insignificant. Following that, the drug release in the
PLGA coating quickly exceeds that of the biodurable coating as a
result of the increasing degradation and erosion of the coating.
The characteristics of the release profiles in intravascular delivery
are in good correspondence to what was reported for in vitro
release [12,32]. In the simulation comparison, the total drug
release is achieved in the PLGA coating at around day 30, while
the biodurable coating has only released 20% of its loading and
remains at very slow releasing rate.
Corresponding to the difference in the release profiles in the
PLGA coating and the biodurable coating, the average drug con-
centrations in the arterial wall starts off with similar levels for
both free drug and bound drug (Fig. 5). The peak drug concentra-
tions appear very early in the biodurable coating case at around
day four, and the drug levels gradually decrease. In the PLGA
coating case, the drug levels keep increasing as a result of acceler-
ated drug release by degradation and erosion in the coating, and
do not arrive at the peaks until around day 22, just a few days
prior to total drug release in the coating at day 30. Compared with
the biodurable coating case, the drug levels in the PLGA coating
Table 1 Summary of model parameters
Parameters of the model domain
Outer diameter of the artery 3 mm [20]
Thickness of the arterial wall 200lm [24,42]
Thickness of the stent strut 140lm [33]
Thickness of stent coating 30 lm [11]
Mesh size for the arterial wall 5lm —
Mesh size for the coating 0.5lm —
Mesh size for the boundary layers 0.2lm —
Parameters of the mathematical model
Drug diffusivity in the initial PLGA polymer, Ds0 10
5lm2/s [32,35]
Drug diffusivity in the aqueous phase, Dl0 50lm
2/s [32,47]
Transmural drug diffusivity in the arterial wall, Dr 10
1lm2/s [40]
Anisotropic ratio of drug diffusivity in the arterial wall, Dh=Dr 10 As derived
Association rate constant, ka 10
4 l/mols [41,51]
Dissociation rate constant, kd 10
2 l/s [41,51]
Internalization rate constant, ki 0 or as mentioned —
Weight-based PLGA degradation rate constant, kw 7.5 107 l/s [39]
Number-based PLGA degradation rate constant, kn 2.5 107 l/s [39]
Molecular weight dependency of diffusivity, a 1.714 [32,36]
Drug partitioning coefficient, j 104 [32,52]
Interstitial flow velocity in the arterial wall,  0 or as mentioned
Initial drug concentration in the coating, C0 10
5 mol/l [22,24]
Initial binding site concentration in the arterial wall, S0 10
5 mol/l [40]
Fig. 2 Illustrated mesh of the model domain. (The actual mesh
used in simulation is much finer).
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case decreased much faster after the peak concentrations. The
faster decrease is contributed by the higher drug levels in the arte-
rial wall which leads to a fast drug clearance rate at the perivascu-
lar interface. In each case, the trends of concentration evolution
for the free drug and the bound drug are highly identical, as a
result of the fast reversible binding process in comparison with
the drug diffusion [22].
Noticeably, the PLGA coating produces overall much higher
drug levels in the arterial wall than the biodurable coating for a
prolonged period, governed by the faster drug release rate in the
coating. In coronary angioplasty procedures, a sustained drug
level in the arterial wall for a prolonged period is necessary for
reducing the restenosis. The biodurable coatings are typically
found to be limited in sustaining a sufficiently high drug level in
the arterial wall after the initial release period, because of the low
drug diffusivity and slow drug release [4]. The simulations sug-
gest that the requirement can potentially be achieved by using a
degradable PLGA coating through the enhanced release by degra-
dation and erosion.
The arterial drug distributions for both free drug and bound
drug are shown for the PLGA coating case at day 25 (Fig. 6),
shortly after the drug levels have peaked in the arterial wall. The
drug distribution is close to uniform in the circumferential direc-
tion, whereas in the transmural direction a gradient is clearly
observed closer to the perivascular interface. The better uniform-
ity in the circumferential direction is expected with the anisotropic
drug diffusivity which results in fast drug diffusion in the circum-
ferential direction. The observed arterial drug distribution pattern
for the PLGA coating case is similar to previous studies of a bio-
durable coating [22]. The comparison indicates that while the
PLGA coating ensures higher overall drug concentrations in the
Fig. 3 Percentage relative error of different mesh sizes com-
pared with the extremely fine reference mesh. (a) Varying mesh
size in the arterial wall with constant mesh size of 1lm in the
coating; and (b) varying mesh size in the coating with constant
mesh size of 5 lm in the arterial wall.
Fig. 4 Comparison of simulated drug release profiles for the
PLGA stent coating (solid) and the biodurable coating (dashed).
(Half strut embedment, ki5 0, and vr50).
Fig. 5 Spatially averaged concentrations of free drug and
bound drug in the arterial wall for the PLGA coating case and
the biodurable coating case. (Half strut embedment, ki5 0, and
vr5 0).
Fig. 6 Drug concentration distribution in the arterial wall at 25
days for intravascular drug delivery from a PLGA stent coating.
Color bar is in logarithmic scale (mol/m3). (Half strut embed-
ment, ki50, and vr5 0).
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arterial wall than a biodurable coating, the arterial drug distribu-
tion pattern is not impacted.
3.2 Impact of Drug Internalization. The drug internaliza-
tion describes the cellular uptake of drug molecules after they as-
sociate with the binding sites, and is an important mechanism for
drug metabolism in the physiological environment [43,44]. Only
limited studies have considered the impact of the internalization
process on the stent-based drug delivery [42]. While the drug
internalization rate may vary for the different drugs, and such data
are lacking in the literature, the proposed model allows different
values to be tested for examining and understanding the potential
impact of drug internalization. Because the internalization process
is in competition with the dissociation step of binding, values of
the internalization rate are investigated based on its relative value
to the dissociation rate constant. To illustrate the drug internaliza-
tion process, the average drug levels in the arterial wall are simu-
lated and plotted in Fig. 7 for the three drug forms using the
proposed drug internalization model, assuming a small internal-
ization rate relative to the dissociation rate (ki ¼ 104kd). The
simulation shows an initial build-up for bound drug, which peaks
and then diminishes as the bound drug gets internalized. Eventu-
ally both free drug and bound drugs are converted to internalized
drug. The drug binding and internalization kinetics are closely
related to that of the well-recognized enzymatic reactions [53],
where in this context the binding sites are acting like enzymes.
Throughout the period, the available binding sites are at abun-
dance in the arterial wall, as revealed by the much smaller average
bound drug levels (<0.15lM) compared with that of the overall
binding sites concentration (10 lM).
Different values for the internalization rate constant are exam-
ined to look at its impact on the drug delivery process and the con-
version among the three drug forms. While the simulations have
shown identical release profiles in the coating for the different
internalization rates, Fig. 8 reveals very different drug allocation
among the different drug forms for internalized drug (Fig. 8(a))
and bound drug (Fig. 8(b)). For very small internalization rate
(ki ¼ 106kd), the bound drug level experiences little change com-
pared with the no-internalization case and very low internalized
drug level was generated. Increasing the internalization rate con-
stant to ki ¼ 104kd, a two orders of magnitude increase in inter-
nalize drug level is observed, while the bound drug concentration
only experiences a small decrease that is more noticeable at later
times. The internalized drug level arrives at constant profiles once
the internalization rate constant exceeds ki ¼ 102kd, whereas the
profiles for the bound drug can still experience drastic decrease
for ki values from 10
2kd to kd. In all cases, the free drug
evolution followed identical trends as the bound drug as a result
of the fast reversible binding process and is therefore not illus-
trated. The simulation results indicate that the arterial drug levels
could have a sensitive response with respect to the different rates
of drug internalization.
Furthermore, the internalization process changes the arterial
drug distribution and significantly affects the drug availability in
different regions of the arterial wall (Fig. 9). At small internaliza-
tion rate (Fig. 9(a)), the arterial wall drug distribution is still close
to uniform in the circumferential direction, similar to the case in
the no-internalization case. The internalized drug distribution,
however, exhibits gradient in both the circumferential and trans-
mural directions and has higher concentration close to the proxim-
ity of the stent strut. With increased internalization rate (Fig.
9(b)), the arterial distribution becomes highly nonuniform for
both bound drug and internalized drug. In the circumferential
direction, the drug levels at areas far away from the stent strut
have decreased drastically. As illustrated with the simulations, the
consequences of drug internalization could lead to significantly
modified arterial drug distribution and reduce the drug availability
at arterial sites that are further away from stent strut. The simula-
tions suggest that drug internalization could increase the likeli-
hood of spatial nonuniformity in arterial drug distribution for
stent-based drug delivery. As reported in previous studies, the spa-
tial nonuniformity of arterial drug distribution is potentially linked
to the growth of more in-stent restenosis at larger interstrut angle
[22,54]. Interestingly, the internalization process could aggravate
the potential adverse effect of low drug levels at arterial sites fur-
ther away from stent strut in reducing in-stent restenosis. The
amount of impact varies with the internalization rate constant and
Fig. 7 Average concentrations of free drug, bound drug, and
internalized drug in the arterial wall for a relatively small inter-
nalization rate constant. (Half strut embedment, vr50, and
ki5 10
4kd).
Fig. 8 Average concentrations in the arterial wall for internal-
ized drug (a) and bound drug (b) at different internalization
rates. (Half strut embedment and vr5 0).
111004-6 / Vol. 136, NOVEMBER 2014 Transactions of the ASME
Downloaded From: http://biomechanical.asmedigitalcollection.asme.org/pdfaccess.ashx?url=/data/journals/jbendy/930797/ on 02/03/2017 Terms of Use: http://www.asme.org/about-asme/terms-of-use
can be determined for a specific drug (such as sirolimus) when ex-
perimental characterization of the rate constant becomes
available.
3.3 Impact of Interstitial Flow. The interstitial flow within
the arterial wall is induced by the pressure difference between the
lumen and the perivascular space and is typically very small (in
the range of 0.01–0.1 lm/s [45]), and the convective transport
term for inside the arterial wall is often left out in the drug trans-
port models of drug-eluting stents [18,20]. A detailed analysis has
been carried out to depict the relative importance of convective
transport to that of diffusive transport, where drug pharmacoki-
netics were absent and the impact of convection transport for a
hydrophobic drug only starts to become apparent for Peclet num-
ber larger than 10 [15]. The interstitial flow velocities can be cal-
culated by Darcy’s Law if the pressure difference and the arterial
wall permeability are known [55]. While the velocity may differ
in different subjects, and the focus of the study was on the impact
of the velocity on drug transport rather than accurate calculation
of the velocity itself, a range of values reasonable for the system
were used [45].
A thorough investigation of the impact of interstitial flow is car-
ried out using our model. As described in Eq. (7), the flow veloc-
ity is nonzero only in the transmural direction. While fluid
momentum equations are not explicitly solved in this work, the
fluid mass conservation equation (the so-called continuity equa-
tion) can be used to show that the velocity vr is inversely depend-
ent on the radius. Considering the small curvature of the arterial
wall (that is, a thin wall thickness compared with the radius of the
lumen), the variation of the velocity in the transmural direction is
negligible, and a constant velocity is assumed in the investigation
of the impact of interstitial flow on the drug transport. The simula-
tions show that the drug release profiles in the PLGA coating is
not affected by the interstitial fluid flow within the arterial wall
for the reported interstitial flow velocities (figure not shown). The
absence of variation in the drug release rate is a result of the sig-
nificantly slower drug diffusion within the PLGA stent coating in
comparison to the mechanisms for drug removal at the exterior of
the coating, which are contributed by both the drug diffusion in
the arterial wall and the wash-out boundary condition at the
coating-lumen interface.
The average drug concentrations in the arterial wall, however,
are significantly impacted by the presence of convection (Fig. 10).
From no interstitial flow to increasing flow velocity, the average
drug concentrations for both free and bound drug decrease signifi-
cantly. While the same drug release rates in the different scenarios
indicate that the same amount of drug passed through the coating-
arterial wall interface, the presence of interstitial flow increases
the transport in the transmural direction and leads to faster drug
clearance at the perivascular interface. With interstitial fluid flow,
the peaking of the average drug concentrations shift toward earlier
times. The Peclet number in the arterial wall is calculated as
pe ¼ vL=Dr ¼ 20 for interstitial flow velocity (vr) of 0.01lm/s
and wall thickness (L) of 200 lm, which confirms the non-
negligible impact of the interstitial flow in drug transport.
The drug distribution shows greatly impaired drug uniformity
in the circumferential direction as a result of the convection with
even low interstitial flow velocity (0.01lm/s) (Fig. 11). Compared
with the case with no interstitial flow (Fig. 6), the convection
results in highly nonuniform distribution in the circumferential
direction. Interestingly, the interstitial flow enhances the uniform-
ity in the transmural direction, especially for areas closer to the
stent strut. However, the drug coverage in the upper layers are im-
portant for reducing in-stent restenosis [56]. Similar to the analy-
sis on the drug internalization, the interstitial flow creates spatial
nonuniformity of drug distribution and leads to lowered drug level
at arterial sites further away from the stent strut, which could
increase the chances of potential adverse outcomes such as in-
stent restenosis growth.
3.4 Impact of Strut Embedment. The strut embedment in
the arterial wall is another important factor that can affect the
drug release in the stent coating and the drug delivery into the ar-
terial wall. Investigation of strut embedment was previously car-
ried out for a biodurable stent coating where the drug binding
pharmacokinetics was absent [20]. The model simulations here
considered three different scenarios of embedment: contact, half-
embedded, and fully embedded. The strut embedment was exam-
ined for its impact on the drug release in the PLGA coating and
Fig. 9 Arterial drug distribution at 25 days for (a) small inter-
nalization rate ki510
4kd, and (b) fast internalization rate
ki5 10
2kd. Color bar is in logarithmic scale (mol/m3). (Half strut
embedment and vr5 0).
Fig. 10 The average drug concentrations in the arterial evolu-
tion at different interstitial fluid flow velocities. (Half strut
embedment and ki50).
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the arterial drug up-take. The arterial wall thickness is used as
300 lm in the simulations in this section.
The simulations show that the drug release profiles in the
PLGA coating for the three different strut embedment overlap
with each other (figure not shown), similar to what was observed
in the cases for different interstitial flow and internalization rates.
The observed negligible impact on the drug release profiles in the
PLGA coating, again, is due to the rate-limiting step of drug diffu-
sion within the PLGA coating.
The average bound drug concentration in the arterial wall
increases with more strut embedment (Fig. 12), which is within
expectation, because with more contacting area of the coating
with the arterial wall, more of the released drug gets into the arte-
rial wall rather than that depletes into the blood stream. The
enhancement of arterial drug levels for higher degrees of strut
embedment is in agreement with findings in a previous study of a
biodurable coating [20]. Interestingly, the drug concentrations all
peak at the same time at around 24 days. The peak drug levels are
roughly proportional to the ratio of the contacting area of the stent
coating with the arterial wall. The fully embedded case has the
highest average drug concentration throughout the time.
The arterial drug distribution for bound drug is shown for the
three different strut embedments in Fig. 13. A transmural drug
concentration gradient is observed in all three cases, with the low-
est drug concentration at the perivascular interface due to the drug
clearance. In the fully embedded case, drug accumulates and
results in the highest drug concentration in the upper layers of the
arterial wall. While enhanced drug concentration in the upper
layers may be beneficial, the increased degree of strut embedment
also indicates more damage to the arterial wall during the stent
expansion process, which could potentially counter the benefit of
increased drug levels.
4 Conclusions
The model developed in this work considers a wide and
detailed scope of physical, chemical, and biological processes
involved in the intravascular drug delivery from a stent with
PLGA coating. A mechanistic model for drug release in the biode-
gradable PLGA coating that couples the drug diffusion with
PLGA degradation and erosion was adopted and integrated with
subsequent drug transport and distribution in the arterial wall that
takes into account anisotropic drug diffusivity and reversible drug
binding in the arterial wall. Theoretical estimation of the aniso-
tropic drug diffusivity was also proposed and analyzed with good
correspondence to the literature.
The simulation comparison of PLGA coating and biodurable
coating has confirmed the difference in drug release rates for
intravascular drug delivery, in accordance with expectations
gained from in vitro release studies. The comparison revealed the
enhanced average drug levels in the arterial wall by utilizing a
PLGA stent coating, while the simulations suggested similar pat-
terns of arterial drug distribution compared to the biodurable coat-
ing case.
Simulation and analysis of factors including drug internaliza-
tion, transmural interstitial fluid flow in the arterial wall, and strut
embedment were carried out. Negligible change in the drug
release profiles in the PLGA coating was observed in all cases, as
a result of the slow drug diffusion within the coating compared
with drug transport at the coating-lumen interface and coating-
arterial wall interface. Higher average drug levels are observed
Fig. 11 Arterial drug distributions for free drug and bound
drug with transmural interstitial flow (v5 0.01lm/s) at day 20.
Color bar is in logarithmic scale (mol/m3). (Half strut embed-
ment and ki5 0).
Fig. 12 The average bound drug levels in the arterial wall for
different strut embedment (ki5 0 and vr5 0)
Fig. 13 Bound drug distribution in the arterial wall at day 25
for (a) a contacting stent strut, (b) a half-embedded strut, and
(c) a fully embedded strut. Color bar is in logarithmic scale
(mol/m3). (ki5 0, and vr5 0).
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for slower interstitial fluid flow velocities and higher degree of
strut embedment. More importantly, each of the investigated fac-
tors can significantly change the drug distributions in the arterial
wall, which can potentially influence the treatment outcomes. The
presence of drug internalization irreversibly consumes and
reduces the drug molecules for diffusion, and can localize drug
concentrations in the arterial wall neighboring the strut. The trans-
mural interstitial fluid flow, even at very slow velocity, depletes
the drug levels at distant arterial sites by convection. Both the
drug internalization and interstitial fluid flow can lead to low drug
levels at distant arterial wall sites away from the strut, which can
potentially impair the drug-eluting stent performance in reducing
restenosis. For the different strut embedment, more strut embed-
ment is found to induce higher drug concentration in the upper
layer of the arterial wall. While the different model factors were
investigated individually in this study in order to acquire insights
on their distinct impacts on the drug transport and distribution,
when more than one model factor are in consideration, a combina-
tion of their individual impact can be expected. For example,
when both drug internalization and interstitial flow are present,
they will both contribute to reduce the drug availability at the sites
far away from the strut in the circumferential direction.
Besides the three factors investigated in detail in this work,
other factors related to the pathological conditions, such as pla-
que, thrombus, and regions of tissue compression due to the stent
implantation, may change the drug transport properties in the arte-
rial wall and can also play an important role in the efficacy of
treatment with drug-eluting stents. While some studies have been
carried out [23,57], such factors were not investigated in this study
and further research efforts are necessary. In addition, this study
was focused on modeling drug delivery and distribution in the cir-
cumferential direction for insights on potentially reducing the
nonuniform circumferential restenosis growth [54], and extension
of the developed model to 3D to include the drug transport in the
axial direction may also be interesting for further investigations.
The developed model here provides the basis of a design tool
for evaluating and studying a PLGA coating for stent applications,
with the ease of adaptation to more sophisticated scenarios (e.g.,
consideration of more pathological conditions). Simulations using
the model help to provide insights into the drug release and distri-
bution by a stent with PLGA coating, as well as the potential
impacts of various factors that can affect the efficacy of drug
delivery. With the developed model, optimization of the model
parameters, such as different stent strut geometries and coating
thickness, can also be performed for exploration on the design of
PLGA-coated drug-eluting stents.
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